期刊文献+

非小细胞肺癌患者EML4-ALK融合基因检测及其与临床病理特征的关系 被引量:19

Detection of EMIA-ALK fusion gene in non.small cell lung cancer and its clinicopathologiccorrelation
原文传递
导出
摘要 目的探讨非小细胞肺癌(NSCLC)中EML4-ALK融合基因的存在情况及其与患者临床病理特征的关系。方法采用特异引物即时荧光PCR法对268例收集于2007年1月至2012年4月间的NSCLC手术切除标本进行EML4-ALK融合基因检测,应用Sanger测序法对其中164例进行验证,并结合临床病理资料分析EML4一ALK融合基因存在情况与患者临床病理特征的关系。结果在268例NSCLC中,有11例存在EML4-ALK融合基因(4.1%)。其中女性EML4-ALK融合基因阳性率(5.9%,5/85)高于男性(3.3%,6/183),两者差异无统计学意义(P=0.503);年龄≤60岁者的EML4-ALK融合基因阳性率(4.3%,6/140)略高于〉60岁者(4.0%,5/124),两者差异无统计学意义(P=0.918);非吸烟者的EML4-ALK融合基因阳性率(6.8%,8/118)高于吸烟者(1.6%,2/123),两者差异无统计学意义(P=0.092);腺癌患者EML4.ALK融合基因阳性率(7.6%,10/132)高于鳞癌患者(1.3%,1/79),两者差异无统计学意义(P=0.094)。抽取164例进行Sanger测序验证,其EML4-ALK阳性检出率与即时荧光PCR法结果一致,两种方法的总体符合率为100%。结论EML4-ALK融合基因在女性、非吸烟、腺癌患者中较为多见,代表了一类新的NSCLC亚型。 Objective To investigate the frequency of EMIA-ALK fusion gene in non-small-cell lung cancer (NSCLC) patients, and its correlation with clinicopathologic features. Methods Real-time PCR was used to detect the presence of EML4-ALK fusion gene in 268 cases of NSCLCs using paraffin- embedded tissue samples (among which 164 samples were re-validated by Sanger sequencing). Related clinicopathological correlation was analyzed. Results EML4-ALK fusion gene was found in 4. 1% (11/268) of the cases. One hundred and sixty four samples were verified by Sanger sequencing, and the overall coincidence of the results of two methods ( Sanger sequencing and Real-time PCR ) was 100% . Female patients (5.9%, 5/85) , ≤60 years of age (4. 3% ,6/140) , non-smokers (6. 8%, 8/118) and adenocarcinomas (7.6% , 10/132) had a higher mutation rate than that in male patients (3.3% , 6/183) , 〉60 years of age (4. 0% ,5/124) , smokers ( 1.6% , 2/132) and squamous cell carcinomas ( 1.3% , 1/79) , although no statistical significance in age ( P = 0. 918 ) , gender ( P = 0. 503 ) , smoking history ( P = 0. 092) and histological type ( P = 0. 094 ). Conclusions Chinese NSCLC patients have a 4. 1% detection rate of EML4-ALK fusion gene in the tumor tissues. Female, non-smoker and adenocarcinoma histological subtype tend to be associated with a higher rate of EMIA-ALK gene fusion.
出处 《中华病理学杂志》 CAS CSCD 北大核心 2013年第4期252-256,共5页 Chinese Journal of Pathology
关键词 肺肿瘤 非小细胞肺 微管相关蛋白质类 癌基因融合 Lung neoplasms Carcinoma, non-small-cell lung Microtubule-associatedproteins Oncogene fusion
  • 相关文献

参考文献17

  • 1Jemal A, Siegel R,Ward E,et al. Cancer statistics. CA Cancer JClin, 2006,56(2) : 106-130. 被引量:1
  • 2Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med, 2009,361(10) : 947-957. 被引量:1
  • 3Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy asfirst-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer ( OPTIMAL, CTONG-0802 ):a multicentre, open-label, randomised, phase 3 study. LancetOncol, 2011,12(8) :735-742. 被引量:1
  • 4Sun Y,Shi Y, Zhang L, et al. A randomized, double-blind phaseIE study of icotinib versus gefitinib in patients with advanced non-small cell lung cancer ( NSCLC ) previously treated withchemotherapy ( ICOGEN ). J Clin Onco, 2011, 29 ( Suppl ):[abstr 7522]. 被引量:1
  • 5Soda M, Choi YL, Enomoto M, et al. Identification of thetransforming EML4-ALK fusion gene in non-small-cell lungcancer. Nature, 2007 , 448(8) : 561-566. 被引量:1
  • 6Hom L, Pao W. EML4-ALK: honing in on a new target in non-small-cell lung cancer. J Clin Oncol, 2009, 27(26) :4232-4235. 被引量:1
  • 7张会娟,张晓彤,张力.EML4-ALK融合基因抑制剂耐药机制的研究进展[J].中华病理学杂志,2012,41(12):862-864. 被引量:5
  • 8Soda M, Takada S,Takeuchi K, et al. A mouse model for EML4-ALK-positive lung cancer. Proc Natl Acad Sci USA, 2008, 105(50) ; 19893-19897. 被引量:1
  • 9Shaw AT, Yeap BY, Solomon BJ, et al. Effect of crizotinib oroverall survival in patients with advanced non-small-cell lun!cancer harbouring ALK gene rearrangement: a retrospectiveanalysis. Lancet Oncol, 2011,12( 11 ) : 1004-1012. 被引量:1
  • 10Zhang X, Zhang S, Yang X,et al. Fusion of EML4 and ALK ifassociated with development of lung adenocarcinomas lackingEGFR and KRAS mutations and is correlated with ALKexpression. Mol Cancer, 2010,9:188. 被引量:1

二级参考文献17

  • 1Ou SH. Crizotinib : a novel and first-in-class muhitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond. Drug Des Devel Ther, 2011,5 : 471-485. 被引量:1
  • 2Doebele RC, Pilling AB, Aisner DL, et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non- small cell lung cancer. Clin Cancer Res, 2012,18 (5): 1472- 1482. 被引量:1
  • 3Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EMIA-ALK fusion gene in non-small-cell lung cancer. Nature, 2007,448(7153): 561-566. 被引量:1
  • 4Sasaki T, Rodig S J, Chirieac LR, et al. The biology and treatment of EMIA-ALK non-small cell lung cancer. Eur J Cancer, 2010,46(10) : 1773-1780. 被引量:1
  • 5Lin E, Li L, Guan Y, et al. Exon array profiling detects EMIA- ALK fusion in breast, colorecta|, and non-small cell lung cancers. Mol Cancer Res, 2009, 7 (9) : 1466-1476. 被引量:1
  • 6Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med, 2010, 363 (18) : 1693-1703. 被引量:1
  • 7Camidge DR, Bang YJ, Kwak EL, et al. Progression-free survival (PFS) from a phase 1 study of crizotinib (PF-02341066) in patients with ALK-positive non-small cell lung cancer ( NSCLC ). J Clin Oncol,2011,29(suppl) :abstr 2501. 被引量:1
  • 8Crino L, Kim D, Riely GJ, et al. Initial phase Ⅱ results with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC) : PROFILE 1005. J Clin Oncol, 2011,29 (suppl) : abstr 7514. 被引量:1
  • 9Weickhardt A J, Rothman MS, Salian-Mehta S, et al. Rapid-onset hypogonadism secondary to crizotinib use in men with metastatic nonsmall cell lung cancer. Cancer, 2012 [ Epub ahead of print]. 被引量:1
  • 10Camidge DR, Doebele RC. Treating EML4-ALK-positive lung cancer-early successes and future challenges. Nat Rev Clin Oncol, 2012,9 (5) :268-277. 被引量:1

共引文献4

同被引文献284

引证文献19

二级引证文献98

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部